Who Paid My Doc
Neil Sardesai
Orthopaedic Trauma Arcadia, CA Medical Doctor
NPI 1275876955 CMS profile 5536039
289 W Huntington Dr Ste 103, Arcadia, CA 91007
General payments
$24,487
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Neil Sardesai of Arcadia, CA is reported in the CMS Open Payments database as having received $24,487 across 98 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 69th percentile of Orthopaedic Trauma profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,251 | 11 | |
| 2024 | General | $2,993 | 10 | |
| 2023 | General | $519 | 8 | |
| 2022 | General | $1,200 | 14 | |
| 2021 | General | $15,951 | 28 | |
| 2020 | General | $247 | 4 | |
| 2019 | General | $1,326 | 23 |
Beside peers
- Neil Sardesai
- Orthopaedic Trauma median
- Middle half of Orthopaedic Trauma
- National median
In program year 2025, general payments to Neil Sardesai were reported at $2,251. Among 734 Orthopaedic Trauma profiles paid that year, the median was $1,227 and the middle half received between $259 and $7,433.
Show as a table
| Year | Neil Sardesai | Orthopaedic Trauma median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,326 | $1,475 | $264–$6,401 | $163 |
| 2020 | $247 | $596 | $120–$4,020 | $114 |
| 2021 | $15,951 | $919 | $171–$4,697 | $132 |
| 2022 | $1,200 | $1,547 | $272–$7,240 | $149 |
| 2023 | $519 | $1,330 | $247–$5,875 | $160 |
| 2024 | $2,993 | $1,288 | $277–$6,797 | $164 |
| 2025 | $2,251 | $1,227 | $259–$7,433 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 6 drugsPart D claims
183
Drug cost
$2,270
Branded share of claims
47%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Naloxone Hcl | Generic | 16 | $706 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 59 | $703 | |
| Oxycodone Hcl | Generic | 38 | $397 | |
| Tramadol Hcl | Generic | 32 | $224 | |
| Ondansetron Odt Ondansetron | Brand | 27 | $169 | |
| Ondansetron Hcl | Generic | 11 | $71 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Records
98 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Orthopaedic Trauma in California
Related records
Orthopaedic Trauma in California
Practitioners in the same specialty and state, ranked by reported value.
All Orthopaedic Trauma
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.